BCRX vs COP · rev $374.7M vs P/E 19, rev $34.92B
BioCryst Pharmaceuticals Inc (BCRX) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
Latest reported COP revenue for 2026-06-30 was $34.92B. Net income was $6.11B. COP currently screens at market cap $135.49B and trailing P/E 18.8.
BCRX currently screens at market cap $1.83B. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the BCRX and COP stock pages for the full models.
Not investment advice.